Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
News and updates on ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) focus on its progress as a clinical stage oncology company developing therapies that address mechanisms of therapeutic resistance in cancer. ORIC regularly reports clinical data, operational milestones, and financial updates that are relevant to investors and observers following the ORIC stock and its development programs.
Recent news highlights include Phase 1b data for ORIC-944 (also referred to as rinzimetostat) in metastatic castration-resistant prostate cancer, where the company has discussed PSA responses, circulating tumor DNA reductions, and a safety profile described as compatible with long-term dosing when combined with androgen receptor inhibitors. ORIC also provides updates on preclinical findings for ORIC-944 in castration-sensitive prostate cancer models and KRAS G12C-mutant NSCLC and colorectal cancer models.
For enozertinib (ORIC-114), ORIC’s news flow includes late-breaking oral and poster presentations at major scientific meetings such as the ESMO Asia Congress. The company reports systemic and CNS activity in non-small cell lung cancer patients with EGFR exon 20, EGFR atypical (including PACC), and HER2 exon 20 mutations, including in patients with active brain metastases. These articles often detail objective response rates, disease control rates, intracranial responses, and safety observations from Phase 1b cohorts.
Corporate news items cover participation in healthcare conferences, strategic pipeline prioritization to focus on ORIC-944 and enozertinib, leadership appointments such as the creation of a Chief Technical Officer role, and capital raises via private placements and at-the-market programs. Financial press releases summarize quarterly results, research and development spending, and the company’s cash and investment position.
This news page aggregates ORIC’s press releases and related disclosures so readers can follow clinical trial readouts, program updates, corporate developments, and other material events affecting ORIC Pharmaceuticals and the ORIC ticker over time.
Summary not available.
ORIC Pharmaceuticals, a clinical-stage oncology company, announced participation in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 2:00 p.m. ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 90 days post-event.
ORIC focuses on developing treatments that address mechanisms of therapeutic resistance, with product candidates including ORIC-533 for multiple myeloma, ORIC-114 targeting genetically defined cancers, and ORIC-944 for prostate cancer. The company operates from South San Francisco and San Diego, California.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage oncology company, presented two preclinical posters at the 2023 AACR Annual Meeting. These presentations highlight the company’s ongoing development of ORIC-944, a PRC2 inhibitor currently in Phase 1 clinical trials targeting metastatic prostate cancer, and progress in their PLK4 inhibitor program aimed at addressing specific breast cancer mechanisms.
The findings revealed that ORIC-944 lowers H3K27me3 levels, supporting its biomarker strategy for the ongoing trial. In the PLK4 program, selective inhibitors exhibited synthetic lethality in TRIM37-amplified cancers. Both programs demonstrate ORIC's commitment to advancing targeted therapies against cancer resistance mechanisms.
ORIC Pharmaceuticals reported significant advancements in its clinical pipeline, driven by three ongoing Phase 1b trials: ORIC-533 for multiple myeloma, ORIC-114 for EGFR/HER2-mutated cancers, and ORIC-944 for prostate cancer. A $25 million equity investment from Pfizer was secured, alongside a collaboration for a potential Phase 2 study of ORIC-533. As of December 31, 2022, the company had $228.2 million in cash and investments, expected to fund operations into the first half of 2025. The R&D expenses for 2022 totaled $61.7 million, reflecting strategic investments in product development.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced two accepted abstracts for poster presentations at the 2023 AACR Annual Meeting, scheduled for April 14-19, 2023. The presentations will showcase preclinical biomarker results for ORIC-944, a selective PRC2 inhibitor in Phase 1 trials for metastatic prostate cancer, and data from its PLK4 inhibitor program. The biomarker strategy for ORIC-944 indicates significant H3K27me3 level reductions in response to treatment. Additionally, selective PLK4 inhibition shows enhanced synthetic lethality in certain cancer models. Both presentations aim to underline ORIC's innovative approach to overcoming therapeutic resistance.
ORIC Pharmaceuticals, a clinical stage oncology company, announced participation in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 2:00 p.m. ET. The discussion will be available via live webcast on the company's investor website, with replays accessible for 90 days post-event.
Focused on overcoming resistance in cancer, ORIC’s product pipeline includes ORIC-533, an inhibitor of CD73 for multiple myeloma; ORIC-114, targeting EGFR and HER2 in various cancers; and ORIC-944, an inhibitor of PRC2 for prostate cancer. Further information is available at www.oricpharma.com.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced on February 1, 2023, the grant of 35,596 non-qualified stock options and 5,948 restricted stock units to three new non-executive employees. These inducement grants are part of the 2022 Inducement Equity Incentive Plan and are contingent on continued employment through each vesting date. The stock options' exercise price aligns with the closing price on the Grant Date. Vesting occurs over a span of time, with 25% vesting after one year and the remainder vesting monthly. The grants were approved by the Compensation Committee in compliance with Nasdaq regulations.
ORIC Pharmaceuticals, a clinical stage oncology company, announced its management's participation in two key investor conferences in February 2023. The Guggenheim Healthcare Talks Oncology Day will feature a fireside chat on February 8 at 3:20 p.m. ET, followed by the Citi 2023 Virtual Oncology Leadership Summit on February 22 at 11:00 a.m. ET. Investors can access live webcasts through the company's website. ORIC is focused on developing treatments targeting mechanisms of resistance in cancer, with product candidates including ORIC-533, ORIC-114, and ORIC-944.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced key updates and milestones for its clinical pipeline on January 9, 2023. The company expects initial Phase 1b data for three ongoing trials—ORIC-533, ORIC-114, and ORIC-944—in the second half of 2023. Additionally, a new candidate was selected for its PLK4 synthetic lethal program targeting breast cancer. With $228 million in cash and investments, ORIC's funding is projected to last through the first half of 2025, supported by a recent $25 million investment from Pfizer.
ORIC Pharmaceuticals, a clinical stage oncology company, announced that CEO Jacob M. Chacko will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 11:15 a.m. PT. The presentation will focus on ORIC's innovative treatments that address therapeutic resistance in cancer, including lead candidates ORIC-533, ORIC-114, and ORIC-944. A live webcast will be available on the company’s investor website, with a replay accessible for 90 days post-event.